Key result
Dynamic cardiomyoplasty improved clinical functional status and decreased heart failure symptoms in survivors over an average follow-up of 9 months.
Why the study?
Does dynamic cardiomyoplasty improve clinical functional status and heart failure symptoms in patients with dilated or ischemic cardiomyopathy?
Observational (n=35)
Does dynamic cardiomyoplasty improve clinical functional status and heart failure symptoms in patients with dilated or ischemic cardiomyopathy?
Dynamic cardiomyoplasty may improve functional status and reduce heart failure symptoms in patients with cardiomyopathy, though device-related complications can necessitate removal and cause subsequent deterioration.
May support symptom relief in cardiomyopathy survivors; leaves open efficacy and safety pending controlled trials.
Thirty-five cardiomyoplasty procedures were performed in five patients with dilated and 30 patients with ischemic cardiomyopathies. Russian-made cardiomyostimulators (CMS) were implanted in these patients. Twenty-one patients underwent a one-step procedure using a left thoracotomy for cardiomyoplasty, while in 14 patients, a two-step procedure that included a mid-line sternotomy was carried out. During the average follow-up period of 9 +/- 2.1 months, studies were carried out that showed in survivors improved clinical functional status and decreased heart failure symptoms. Evidence of revascularization of the ischemic myocardium from the latissimus dorsi muscle (LDM) wrap was obtained by angiography and radioactive scintigraphy. In five patients, the CMS had to be removed due to complications, and in all these patients, their clinical functional status deteriorated following the cessation of cardiomyostimulation.
No takes yet. Share an insight, caveat, or question.
Krivoschekov et al. (1995) conducted an observational in Dilated and ischemic cardiomyopathies (n=35). Dynamic cardiomyoplasty was evaluated on Clinical functional status and heart failure symptoms. Dynamic cardiomyoplasty improved clinical functional status and decreased heart failure symptoms in survivors over an average follow-up of 9 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: